

LISTING OF CLAIMS

This listing of claims will replace all prior versions, and listings, of claims in the application:

1. - 28. (Cancelled).

29. (Previously presented) A method for the treatment of a T cell-mediated or T cell-dependent autoimmune disease by suppressing an autoimmune response associated with said disease in a human presenting with said autoimmune response, said method comprising orally or enterally administering to said human at least one antigen in an amount effective to suppress said autoimmune response, said antigen selected from the group consisting of autoantigens specific for said autoimmune disease, said suppression comprising elicitation of suppressor T cells specific to said administered antigen.

30. (Cancelled).

31. (Original) The method of claim 29 wherein said autoantigen is administered orally.

32. (Original) The method of claim 29 wherein said autoantigen is administered enterally.

33. (Original) The method of claim 29 wherein said autoimmune disease is multiple sclerosis.

34. (Cancelled).

35. (Previously Presented) A method of treating a T cell-mediated or T cell-dependent autoimmune disease by suppressing an autoimmune response associated with said disease in a human presenting with said autoimmune response, said method comprising orally or enterally administering to said human at least one antigen in an amount effective to suppress said autoimmune response, said antigen selected from the group consisting of autoantigens specific for said autoimmune disease.

36. (Cancelled).

37. (Previously Presented) The method of claim 35 wherein said disease is multiple sclerosis and said autoantigen is bovine myelin basic protein.

38. (Original) The method of claim 35 wherein said autoantigen is contained in tissue that is the site of attack in the autoimmune disease.

39. (Cancelled).

40. (Original) The method of claim 35 wherein said autoantigen is contained in tissue that is the site of attack in the autoimmune disease.

41. (Cancelled).

42. (New) A method of suppressing an autoimmune response in a human presenting with said autoimmune response, said method comprising orally or enterally administering to said human at least one antigen in an amount effective to suppress said autoimmune response, said antigen selected from the group consisting of autoantigens specific for said autoimmune disease.